The MSO is also purchasing a large-scale 120kW Radiant Energy Vacuum (“REV™”) machine for use at its existing cultivation facility. The 120kW REV™ machine is anticipated to be commissioned before the end of the 2021 calendar year.
Prior to committing to using REV™ technology, the MSO conducted extensive tests to confirm the advantages of using REV™ versus incumbent drying methods. The tests used REV™ as a method for drying for multiple strains, and included several controlled benchmark studies to confirm the improved retention of terpenes and cannabinoids. The terpene and cannabinoid levels of the REV™-dried samples were clearly superior to the conventional room/rack dried flower. Further, the smoke experience of REV™-dried cannabis when compared to existing product was undiscernible.
The MSO’s testing employed EnWave’s Terpene Max™ drying protocol, which offers a fast, gentle drying method that removes moisture homogenously from cannabis at controlled, low temperatures, which are below the point where decarboxylation occurs. When compared to other drying methods, REV™ protocols can be customized to improve terpene retention while preserving equivalent or higher cannabinoids. Typically, cannabis flowers dried using the Terpene Max™ program yield greater than 10% more retained terpenes than room/rack dried flower. Bioburden is also materially reduced when using select REV™ protocols. Drying times are reduced from multiple days to less than two hours using REV™ technology.
A single 120kW REV™ machine will process in excess of 200lbs of wet cannabis biomass per hour, yielding approximately 45lbs of dried finished product. That translates into over 200,000lbs of dried cannabis produced per year. REV™ machinery is manufactured for GACP compliance and GMP upon request.
Redeployment of REV™ Machine and Termination of License
Concurrent with the signing of the License, the Company terminated a commercial license agreement previously announced on
To facilitate the commissioning (before year end) of the 120 kW REV™ machine sold to the MSO,
About EnWave
REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV™ technology. It has signed over forty royalty-bearing licenses to date in twenty countries worldwide. In addition to these licenses,
- nutraREV® which is a drum-based system that dehydrates organic materials quickly and at low cost, while maintaining high levels of nutrition, taste, texture, and colour; and,
- quantaREV® which is a tray-based system used for continuous, high-volume low-temperature drying.
More information about
Mr.
President and CEO
For further information:
E-mail: bcharleton@enwave.net
E-mail: dhenriques@enwave.net
For Media Inquiries:
Email: media@enwave.net
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing, are forward-looking statements. All third-party claims referred to in this release are not guaranteed to be accurate. All third-party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the
Source:
2021 GlobeNewswire, Inc., source